#Single Nucleotide Polymorphism (SNP) Genotyping Market

[soumyafwr]

https://carbonfacesocial.org/blogs/80773/Single-Nucleotide-Polymorphism-SNP-Genotyping-Market-Size-Analysis-and-Forecast

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[farmacuticals]

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

[harshnews]

Plant Genomics Market Size, Share, Trends, Growth Opportunities and Competitive Outlook

"Global Plant Genomics Market - Industry Trends and Forecast to 2029

Global Plant Genomics Market, By Type (Molecular Engineering, Genetic Engineering and Genome Editing and Others), Trait (Yield Improvement, Disease Resistance, Herbicide Tolerance and Others), Objective (DNA Extraction & Purification, DNA/RNA Sequencing, Genotyping, Gene Expression Profiling, Marker-Assisted Selection, GMO-trait Purity Testing, Hybrid Purity Testing, Targeted Resequencing, DNA Parentage Testing, QTL Mapping,  and Genetic Disease), Application (Cereals & Grains, Oilseeds & Pulses, Fruits & Vegetables, Sugar Crops, Ornamentals and Alfalfa), Country (U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- On the basis of application, the plant genomics market is segmented into transcriptomics, proteomics, metabolomics, and others. Transcriptomics involves the study of RNA molecules to understand gene expression levels, while proteomics focuses on studying proteins to unravel their functions. Metabolomics analyzes the metabolites within a cell or organism to gain insights into metabolic pathways and biochemical processes.

- In terms of technique, the market can be categorized into molecular markers, DNA sequencing, gene expression analysis, and other techniques. Molecular markers such as SSRs (Simple Sequence Repeats) and SNPs (Single Nucleotide Polymorphisms) are crucial for genetic mapping and marker-assisted breeding. DNA sequencing plays a fundamental role in deciphering plant genomes, while gene expression analysis helps in understanding how genes are regulated and activated.

- Based on end-users, the plant genomics market is segmented into academic research institutes, biotechnology companies, pharmaceutical companies, and others. Academic research institutes are at the forefront of exploring new frontiers in plant genomics, while biotechnology and pharmaceutical companies leverage genomics data for developing genetically modified crops, novel therapeutics, and plant-based products.

**Market Players**

- Some prominent players in the plant genomics market include Illumina Inc., Thermo Fisher Scientific Inc., Eurofins Scientific, Qiagen, Agilent Technologies, Biomatters Ltd., KeyGene, Danaher, LC Sciences, and PerkinElmer. These companies are heavily invested in developing cutting-edge genomics technologies, such as next-generation sequencing platforms, bioinformatics tools, and molecular markers for precision breeding programs. Illumina, in particular, is known for its high-throughput sequencing systems that have revolutionized genomics research across various sectors.

- Additionally, academic research institutions like the Boyce Thompson Institute, Max Planck Institute for Plant Breeding Research, and John Innes Centre play a significant role in advancing plant genomics through collaborative research, knowledge sharing, and technology transfer. ThesePlant genomics market is experiencing significant growth due to the increasing demand for sustainable agriculture practices, rising food security concerns, and advancements in genomic technologies. The application segment of the market plays a crucial role in understanding the complexities of plant biology. Transcriptomics, proteomics, and metabolomics provide valuable insights into gene expression, protein functions, and metabolic pathways, respectively, enabling researchers to develop crop varieties with desirable traits such as higher yield, stress resistance, and nutritional content. As the understanding of plant genomes deepens, the potential for targeted genetic modifications and precision breeding increases, driving the growth of the plant genomics market.

Technological advancements have propelled the plant genomics market forward, with molecular markers, DNA sequencing, and gene expression analysis being key techniques for studying plant genomes. Molecular markers like SSRs and SNPs are essential for genetic mapping and marker-assisted breeding programs, leading to the development of improved crop varieties with increased productivity and resilience to biotic and abiotic stresses. DNA sequencing has revolutionized the field of genomics by enabling the rapid and cost-effective decoding of plant genomes, facilitating genome-wide association studies and comparative genomics analyses. Gene expression analysis complements sequencing data by providing insights into how genes are regulated and function under different environmental conditions, offering valuable information for crop improvement strategies and trait selection.

The plant genomics market is driven by a diverse set of end-users, including academic research institutes, biotechnology companies, and pharmaceutical companies. Academic institutions play a crucial role in fundamental research and discovery, pushing the boundaries of plant genomics through collaboration and knowledge sharing. Biotechnology and pharmaceutical companies leverage genomics data to develop genetically modified crops, biopharmaceuticals, and plant-based products with enhanced traits and functionalities. These industry players drive innovation in plant genomics by translating research findings into practical applications that address global challenges such as food insecurity, climate change, and sustainable agriculture practices.

Prominent market players such as Illumina Inc., Thermo Fisher Scientific Inc., and Qiagen are at the**Segments:** - Molecular Engineering - Genetic Engineering and Genome Editing - Others

**Trait:** - Yield Improvement - Disease Resistance - Herbicide Tolerance - Others

**Objective:** - DNA Extraction & Purification - DNA/RNA Sequencing - Genotyping - Gene Expression Profiling - Marker-Assisted Selection - GMO-trait Purity Testing - Hybrid Purity Testing - Targeted Resequencing - DNA Parentage Testing - QTL Mapping - Genetic Disease

**Application:** - Cereals & Grains - Oilseeds & Pulses - Fruits & Vegetables - Sugar Crops - Ornamentals - Alfalfa

Global Plant Genomics Market is witnessing remarkable growth driven by advancements in genomic technologies and the increasing demand for sustainable agriculture solutions. The market segments based on molecular engineering, genetic engineering, and genome editing are pivotal in shaping the future of plant genomics research and application. Traits like yield improvement, disease resistance, and herbicide tolerance are key focus areas for developing genetically modified crops with enhanced characteristics. Objectives such as DNA extraction, genotyping, and gene expression profiling are instrumental in unraveling the genetic makeup of plants for targeted breeding and trait selection, contributing to agricultural innovation and productivity.

The application of plant genomics spans across various crops such as cereals, oilseeds, fruits, and vegetables, addressing specific needs in different agricultural sectors. The global market analysis

Major Points Covered in TOC:

Plant Genomics Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, Plant Genomics Market portions by application, study goals, and years considered.

Plant Genomics Market Landscape: Here, the opposition in the Worldwide Plant Genomics Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.

Plant Genomics Profiles of Manufacturers: Here, driving players of the worldwide Plant Genomics Market are considered dependent on deals region, key items, net edge, income, cost, and creation.

Plant Genomics Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide Plant Genomics Market is profoundly examined based on areas and nations like North America, Europe, China, India, Japan, and the MEA.

Plant Genomics Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Plant Genomics Market.

Plant Genomics Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.

Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

Browse Trending Reports:

Forage Harvester Market Calcify Uremic Arteriolopathy Drug Market Alexipharmic Drugs Market Resectoscope Market Coal To Liquid Market Air Electrode Battery Market Power Sports Batteries Market Body Scrub Market Cataplexy Treatment Market Alveolar Capillary Dysplasia Treatment Market Quantum Computing Market Control Valves Market Hemodialysis Peritoneal Dialysis Market Breathable Films Market Utility Locator Market Food Humectants Market Electronic Safety System Market Reporter Gene Assay Market Security Assertion Markup Language Saml Authentication Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[niranjan20]

Single Nucleotide Polymorphism (SNP) Genotyping Market" that assess industry size, share & forecast 2026.

[adityarana1687-blog]

Genotyping Market To Surge Beyond $46.5 Billion By 2030

The global genotyping market size is expected to reach USD 46.5 billion by 2030, expanding at a CAGR of 15.6%, according to a new report by Grand View Research Inc. Factors such as the rising prevalence of genetic diseases, rising awareness and research for personalized medicine, and increasing R&D funding for genomics research is expected to contribute to this growth.

Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market. For instance, in August 2019, NIH funded USD 4.6 million initial grants to Color, a health technology company, for precision medicine initiatives and development. Similarly, in 2018, the Government of Australia launched the Australian Genomics Health Futures Mission initiative. The government will provide USD 500 million over a period of 10 years for this mission, and the funding will be sourced from Medical Research Future Fund to improve the testing and diagnosis of genetic diseases and for the development of personalized medicine.

An increase in the prevalence of diseases such as cancer, Alzheimer’s disease, and Parkinson’s disease is another factor that is anticipated to drive demand for genotyping-based diagnostic testing. For instance, Roche has products such as Cobas HCV GT products for cervical cancer diagnosis. Additionally, 23&Me provides genetic testing for medical conditions, such as Parkinson's disease and Alzheimer’s disease.

Failed clinical trials cost companies millions of dollars and therefore companies group patients according to their genotypes. Single Nucleotide Polymorphisms (SNP) based genotyping is increasingly being used in pharmacogenomics to study the effect of genetic variations on the difference in response to therapeutics. Genotyping-based treatment administration also helps in overall cost savings.

The COVID-19 pandemic increased the demand for genotyping-based research activities for the development of COVID diagnostics, vaccines, and therapeutics. Many companies, including Qiagen and Thermo Fisher Scientific, have now launched COVID-19 genotyping kits as a result of the growing demand.

Key players leverage strategic partnerships and new product launches to increase their product offerings. For instance, in January 2020, Illumina and Roche entered into a partnership for improving patient access to oncology genomic testing by assay development. Similarly, in June 2021, the Center for Aquaculture Technologies collaborated with Neogen Corporation to provide high-quality genotyping services tailored to aquaculture producers’ specific demands.

Request a free sample copy or view report summary: Genotyping Market Report

Genotyping Market Report Highlights

The reagents & kit segment accounted for the largest share of 61.6% in the market in 2021. This is attributed to increased demand for genetic testing, increased R&D spending, and increased genotyping testing volumes

PCR segment dominated the market in 2021, whereas sequencing is expected to expand at the highest CAGR during the forecast period. This is due to advantages of the technique, such as low cost per sample, reduced bias as compared to arrays, comparative analysis across samples with no reference genome

Pharmacogenomics is estimated to be the fastest-growing application segment during the forecast period due to increased usage of genotyping in drug development to reduce attrition of products in clinical development

North America accounted for the largest market share in 2021, owing to proactive government measures, high disease prevalence, technological advancements, and advanced healthcare infrastructure

Genotyping Market Segmentation

Grand View Research has segmented the global genotyping market based on product, technology, application, end-use, and region:

Genotyping Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Sequencers & Amplifiers

Analyzers

Reagents and kits

Services

Genotyping Services

Genotyping Technology Outlook (Revenue, USD Million, 2018 - 2030)

PCR

Real-time PCR

Digital PCR

Capillary Electrophoresis

Amplified Fragment Length Polymorphism

Restriction Fragment Length Polymorphism

Single-Strand Conformation Polymorphism

Microarrays

DNA Microarrays

Peptide Microarrays

Others

Sequencing

Next Generation Sequencing

Pyro Sequencing

Sanger Sequencing

Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy

Others

Genotyping Application Outlook (Revenue, USD Million, 2018 – 2030)

Diagnostics

Drug Discovery and Development

Personalized Medicine

Academic Research

Agriculture

Others

Genotyping End-Use Outlook (Revenue, USD Million, 2018 – 2030)

Pharmaceutical And Biopharmaceutical Companies

Diagnostics And Research Laboratories

Academic Institutes

Others

Genotyping Regional Outlook, by Revenue (USD Million, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

List of key players in the Genotyping Market

Illumina Inc.

Thermo Fisher Scientific Inc.

Qiagen Inc.

F. Hoffmann-La Roche Ltd.

Fluidigm Corporation

Danaher Corporation

Agilent Technologies

Eurofins Scientific Inc.

GE Healthcare Inc.

Bio-Rad Laboratories Inc.

[industryforecastnews]

Genotyping Market Size Worth $37.1 Billion By 2024 | Global and Regional Forecast | Grand View Research, Inc.

The global genotyping market size is expected to reach USD 37.1 billion by 2024 according to a new report by Grand View Research, Inc. The increasing demand for genotyping tests to evaluate drug efficacy and safety is one of the major drivers for the genotyping market. Genotyping tests are widely used in selecting a highly responsive, patient population subset against a specific drug candidate before initiating clinical trials. The rising need for affordable genotyping services coupled with the high demand for personalized medicines is also expected to propel the market growth. 

Major pharmaceutical companies are collaborating with diagnostic manufacturers for the development of novel biomarker-based therapeutics. Significant opportunities for the growth of this market are anticipated due to the above-mentioned collaborative initiatives. 

The increasing awareness for prenatal genetic testing pertaining to early detection of chromosomal abnormalities in the high-risk population, the introduction of technological advancements, and the increasing R&D funding are the other factors accentuating the market growth over the forecast period. 

The rising prevalence of genetic diseases, such as Parkinson’s, turner syndrome, and Alzheimer’s is the high impact rendering driver for the market growth. Genotyping facilitates rapid sequencing and the early diagnosis of these aforementioned diseases further aid healthcare professionals to decide on probable treatment options.

Companies are undertaking R&D initiatives for the development of advanced products to cater to the increasing demands of the target population. For instance, in 2014, Fluidigm Corporation introduced the Juno 96.96 Genotyping IFC that analyzes a large number of DNA samples for Single Nucleotide Polymorphisms (SNPs) in a short time span.

Browse Full Report (Tables & Figures) @ https://www.grandviewresearch.com/industry-analysis/genotyping-market

Contact Us:

Grand View Research, Inc. 201 Spear Street 1100, San Francisco, CA 94105 United States

Phone: 

1-415-349-0058

Toll Free: 

1-888-202-9519

[soumyafwr]

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[starmarketingz]

What You Should Do With Your MLM Software

One absolutely remarkable application that many people overlook is its capacity to improve your SEO elements and divert more relevant visitors to your website. You can start an Ecommerce business by creating your own Ecommerce portal (website). There are numerous open-source eCommerce technologies available. Every niche, including multi-level marketing organisations, has a software product that meets their demands. Different organisations or groups may be working on strikingly similar enterprises and launching them on the same day, even if they are unaware of one another. A total of 52 markers showed significant relationships with at least one of the predicted attributes, suggesting that they could be used for marker-assisted breeding. Because of the discovery of additional marker-trait connections, it is possible that both marker approaches should be used in genome-wide association studies. Furthermore, when the results were compared to those generated utilising the Illumina GoldenGate BeadArray Technology, it was discovered that the amount of connections for corresponding traits observed differed depending on the marker system. The set of winter barley cultivars was re-analyzed using Diversity Arrays Technology (DArT) markers to uncover additional associations and to determine whether the marker type changes the outcome of association genetics investigations.

 A set of about 100 winter barley (Hordeum vulgare L.) cultivars was previously genotypically characterised by single nucleotide polymorphism (SNP) markers using the Illumina GoldenGate BeadArray Technology to detect associations with phenotypic data estimated in three-year field trials. Most other platforms are multi-tenant, which implies that all customers are essentially using the same one-size-fits-all platform, with only data security separations given. Three indices, including the Simple Ratio Index (SRI), the Normalized Difference Spectral Index (NDSI), and the Differential Spectral Index (DSI), were created for correlation analysis and to identify the best wavelength combination for biochemical components. In the aforementioned calculations, the reflectance of two random wavelengths was utilised to compute the value of SRI, NDSI, and DSI, respectively, until all wavelength combinations were used. Pearson correlation analysis was then performed on the resulting SRI, NDSI, and DSI. Finally, the traits with an adequate coefficient covariant and normalised distribution underwent hyperspectral trait extraction and Pearson correlation analysis for GWAS analysis. The biological components that did not match the aforementioned condition will not be employed in subsequent correlation analysis.

Air-dried rice seeds were sent to the China National Rice Research Institute (CNRRI) in Zhejiang province, China, to be measured for four biochemical components important for determining rice quality based on national rice standards NY/T593, including Crude Protein Content (PC), Amylose Content (AC), Gel consistency (GC), and Alkali Spreading Value (ASV) (Table 1). Fig. 1 summarises the complete description of the analytical workflow chart for this study. The following criterion was used to evaluate the dataset's validity during statistical analysis: if the data was not regularly distributed, the dataset was rejected. To acquire hyperspectral data, approximately 3 grammes of rice seeds were employed. To collect hyperspectral data, an ASD FieldSpec4 Hi-Res Spectroradiometer (Serial number 18577, Analytical Spectral Devices, Inc., Boulder, Colorado, USA) with a wavelength range of 350-2500 nm was employed. The spectroradiometer automatically repeated the spectrum acquisition process three times for each sample before averaging them to represent the sample's mean spectral reflectance. Vendors might sometimes include unnecessary mandatory features and charge more for them. The grain of rice

 In a petri dish, grains were placed (diameter: 8 cm). Rice seeds were harvested from five plants of each rice type and tested for nine phenotypic features as planned (Table 1). After harvesting, rice seeds were collected and dried naturally by air-drying before being placed in labelled paper sample bags and delivered to Zhejiang University's Key Laboratory of Spectroscopy Sensing (KLSS). All samples' average spectra were extracted. Before re-sequencing, leaf samples were wrapped in aluminium foil and placed in liquid nitrogen for 2 hours before being stored at 80 °C overnight. We compiled the greatest materials available on the internet to assist you in launching your own software company. The Vienna General Hospital developed and implemented a fuzzy and knowledge-based system to identify and monitor NIs in intensive care units (ICUs) in accordance with the European Surveillance System HELICS (NI definitions drawn from the Centers for Disease Control and Prevention (CDC) guidelines).

Contact Us for MLM Software In India

 Our Network : MLM Software | MLM Software in Jaipur | MLM Software in Bhopal | MLM Software in Lucknow | MLM Software in Kolkata

www dot mlmsoftwarez dot in

Helplines : +91-92140-60999

WhatsApp : +91-92140-60999

This content originally appeared on LinkedIn Pulse - the place to gain and share knowledge, empowering people to learn from others and better understand the world.

[marketreportoutlook]

Single Nucleotide Polymorphism Genotyping Market Size, Share, Growth Opportunity and Trends by Growing CAGR till 2026

The global Single Nucleotide Polymorphism Genotyping Market research report 2021 available on DecisionDatabases covers top company players in various countries along with analyzing the market trends and growth rate. Segment analysis by types and application helps in bifurcating the Single Nucleotide Polymorphism Genotyping Market and understand each product type. This report provides information on various market factors such as market size, share, manufacturer's data, growth, and forecast till 2026

The key market players for the global Single Nucleotide Polymorphism Genotyping market are listed below:

Illumina

Luminex Corporation

Agilent Technologies

Affymetrix

Qiagen

Applied Biosystems

Bio-rad

Roche

Beckman Coulter

Enzo Life Sciences

Douglas Scientific

HuaGene Biotech

Sequenom

Benegene

BGI

GenScript

Ocimum Biosolutions

Generay Biotech

Beijing Sunbiotech

Others

Click here to get a FREE Sample Copy of the Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-26639

The Global Single Nucleotide Polymorphism (SNP) Genotyping Market Report is equipped with market data from 2016 to 2026. The report gives a market overview covering key drivers and risk factors. The report is bifurcated by top global manufactures mentioning sales, revenue, and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2021 to 2026. The detailed sales channel is also covered in the study.

COVID-19 Impact Analysis on Single Nucleotide Polymorphism Genotyping Market

The global pandemic COVID-19 has affected the Single Nucleotide Polymorphism (SNP) Genotyping market directly or indirectly. This study covers a separate section giving an explicitly clear understanding of the aftereffects of this pandemic. The detailed study highlights the probable outcomes of this global crisis on the Single Nucleotide Polymorphism (SNP) Genotyping industry. The impact study on production, supply-demand, and sales provides a holistic approach to the future.

Do You Have Any Query Or Report Customization? Ask Our Market Expert @ https://www.decisiondatabases.com/contact/ask-questions-26639

Why Purchase this Report?

A robust research methodology has been followed to collect data for the report. Data, thus collected passes through multiple quality checks to ensure the best quality is served.

The report gives a holistic view of the competitive scenario of the Single Nucleotide Polymorphism (SNP) Genotyping market

The latest product launches along with technological changes and development are covered in the report.

The data analysis in the report helps in understanding the anticipated Single Nucleotide Polymorphism (SNP) Genotyping market dynamics from 2021 to 2026.

DecisionDatabases has a vast repository of data, therefore, we can accommodate customized requirements also.

The graphs, tables and pie charts, and info-graphics covered in the report will help in a better understanding of the report.

The market drivers, restraints, upcoming opportunities, and anticipated restraints cited in the report will assist in making an informed decision.

To better understand the market scenario, the Single Nucleotide Polymorphism (SNP) Genotyping market is segmented as below:

By Types:

Transversion

Transition

By Applications:

Diagnostics

Animal

Plant

Research

Others

By Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

The Middle East and Africa (Turkey, GCC, Rest of Middle East)

The content of the study subjects includes a total of 14 chapters:

Chapter 1: To describe Single Nucleotide Polymorphism (SNP) Genotyping product scope, market overview, market opportunities, market driving force, and market risks. Chapter 2: To profile the top manufacturers of Single Nucleotide Polymorphism (SNP) Genotyping, with price, sales, revenue, and global market share of Single Nucleotide Polymorphism (SNP) Genotyping in 2018 and 2019. Chapter 3: The Single Nucleotide Polymorphism (SNP) Genotyping competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4: The Single Nucleotide Polymorphism (SNP) Genotyping breakdown data are shown at the regional level, to show the sales, revenue, and growth by region, from 2015 to 2020. Chapter 5 and 6: To segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020. Chapter 7, 8, 9, 10 & 11: To break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2016 to 2021 and Single Nucleotide Polymorphism (SNP) Genotyping market forecast, by regions, type, and application, with sales and revenue, from 2021 to 2026. Chapter 12, 13 & 14: To describe Single Nucleotide Polymorphism (SNP) Genotyping sales channel, distributors, customers, research findings and conclusion, appendix, and data source.

Directly Purchase the Complete Global Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-26639

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

[biomedgrid]

Biomed Grid | Hybrid Rice Technology: An Overview

Introduction

The prevalence of today’s environmental contaminants is unprecedented. The Toxic Substance Control Act Chemical Substance Inventory lists over 85,000 chemicals in the U.S. market [1]. Adapting to persistent organic pollutants (POPs) exposures is difficult, particularly if adaptive responses require novel genetic variation [2]. An individual’s fitness is influenced by the sum of all stressors, which can be additive, antagonistic, and/or synergistic [3-5]. Devising effective long-term risk-assessment and mitigation strategies is complicated further by human-induced selection pressures on natural populations (climate change, habitat conversion…), jeopardizing organisms’ abilities to survive and adapt to acute and chronic environmental contaminants. Identifying and quantifying such adaptations in individuals and populations in their natural setting is difficult. Yet, technological advances in next generation sequencing (NGS) and transcriptomics provide an opportunity to infer statistically and biologically relevant information within complex but manageable data sets.

POPs are toxic organic compounds resistant to environmental degradation. Most are anthropogenic, lipid-soluble and can cause adverse impacts on the environment and human health. Many POPs are industrial chemicals - solvents, pesticides, insecticides and fungicides, pharmaceuticals, polychlorinated biphenyls (PCBs), dioxins (PCDD), polyfluorinated dibenzofurans (PCDFs), etc. [6,7]. Due to their general use, POPs have high environmental concentrations; many are hydrophobic and bioaccumulate through the food chain due to their slow rate of metabolism [8-10]. Human and animal exposures are mostly through diet (90%), environmental exposures, and during embryo/fetal development via maternal deposition. Chronic POPs exposures can result in acute and chronic toxicity, demonstrated by developmental defects, chronic illnesses, and increased mortality [6]. Some are categorized as carcinogens [11] while many are endocrine disruptors [12-14] and may affect nervous, immune, digestive, urinary and reproductive systems [6]. Low-level exposure to POPs during critical fetal development stages can have a lifetime effect [12-15]. POPs concentrations in human serum increase with age and seem to be higher in females than males [16]. Evolutionary responses and adaptations to POPs have been documented since the mid-20th century; initially as pesticide resistance cases among invertebrates and plants [17,18], then among other natural populations, including vertebrates and mammals [19,20]. Although industrial toxic chemicals were provoking rapid evolutionary response among natural populations, their effects were mostly ignored.

To evaluate temporal and spatial exposure risks, government agencies study the most environmentally prevalent POPs by examining bioavailability and dose-response relationships in the laboratory setting [21]. Such assessments are limited within relatively static laboratory settings. For organisms exposed to a mixture of POPs, the adverse effects are assumed to be additive as mixtures of POPs can result in synergistic effects, enhancing the toxicity of each compound [3-5]. However, responses to POPs are complex and should be carefully considered when quantifying evolution’s role in mechanisms of sensitivity and resistance to complex mixtures of pollutants within and between natural, genetically variable populations [22,23]. Evolutionary changes due to a chronic POP exposure can be quantified in just a few generations [24,25] and include physiological, genetic and epigenetic transgenerational effects influenced by natural selection: studies utilizing natural populations report phenotypic and molecular consequences, including increased mutation rates, receptor desensitization, phenological traits and epigenetic effects [26,27]. While some exposure effects are adaptive, others reduce population size, causing inbreeding depression or genetic drift [28,29] and decreased genetic variation, compromising the ability to adapt to future stressors. Adaptation to POPs can evolve at a cost, such as increased subsequent sensitivity to oxidative stress [30]. Risk assessment of environmental exposures to complex chemical mixtures should not be limited to often oversimplified and outdated controlled laboratory bioassays focused on robust acute and chronic toxicity endpoints such as survival and reproductive viability of model organisms lacking inherent genetic variation.

The post-industrial age of overwhelmingly complex chemical exposures coupled by recent technological advancements in NGS methodology allows for the utility of diverse non-model organisms within an evolutionary context in public health risk assessment. Scientists started using population genomic approaches to study natural populations lacking robust genomic resources a decade ago. Given that genome sequences of non-model organisms are accumulating at an unprecedented pace, with 234 animal and 319 contig genome assemblies currently in development [31], technological advancements in high-throughput sequencing from non-model organisms generate critically important data to infer complex genotype- environment interactions in a natural setting. Population genomic studies target the underlying variation found in the DNA among individuals and populations. They also utilize genome-wide sampling of sequence variation under the premise that demography and the evolutionary history of populations affect neutral loci similarly, whereas loci under selection will be affected differently [32]. Data of multiple, although individually analyzed, loci from natural populations enables studies of the genomic evolution, acclimatization, and adaptation to strong selective pressure such as pollution exposure in natural environment. Such data sets can yield insights about population processes and variance of allelic diversity within and between populations. The advantage is that an a priori choice of biomarkers of an adverse effect is not necessary, which is important when organisms are exposed to complex chemical mixtures in their natural environment and biomarkers of exposure are not well established [33]. Moreover, adaptation-related projects looking for genomic signatures of selection within and between natural populations can take advantage of established adaptative phenotypes to environmental gradients.

A typical population genomic study platform consists of sequencing strategy design, generation of sequence data, mapping of sequence reads to the assembly, genotyping, and population genetic/ molecular evolutionary analyses. A sequencing strategy includes depth of coverage and utility of individuals vs. pooled samples, number of individuals per population and number of populations, gender, and the need for outgroup species. High-throughput genotyping of millions of markers simultaneously is available for model organisms. Whole transcriptome sequencing has advantages but is expensive since multiple individuals need to be sequenced to represent the population adequately. Moreover, the analysis of short sequence reads depends on an incomplete reference genome to which sequence reads are aligned. Such sequencing platforms generate massive data sets, meaning that inferring statistical and biological relevance can be challenging. Although most non-model natural population genomes are not yet sequenced, reasonably robust, lower throughput, custom platforms are available. Expressed sequence tags (ESTs) have been developed and used as genome-wide gene expression data within and among natural fish populations historically exposed to chemical pollution. New sequencing technologies such as Roche (454) FLX, Illumina Genome Analyzer, ABI SOLiD, and HeliScope sequencing [33] can be used to sequence thousands of transcripts quickly and cost-effectively, making transcriptomic studies possible in virtually any species. Transcriptomics and population genomics can influence studies of diverse species and populations that ask important ecological, physiological, and evolutionary questions with respect to pollutant exposure. High-throughput sequencing allows enough sequencing depth to gain an adequate representation of all the expressed transcripts and has been used for whole transcriptome sequencing [34]. The coding sequences of the expressed transcripts can be analyzed for mutations, altered splice sites, and protein polymorphisms.

Whole transcriptome approaches can identify significant changes in gene expression that are biologically important, but the genomic basis underlying altered patterns of gene expression is mostly unknown. Once many genetic markers became available, population geneticists began scanning genomes for reduced nucleotide diversity, extended linkage disequilibrium, or regions of homozygosity as potential selection signatures. This approach requires that large numbers of loci and genetic markers are statistically analyzed for non-random patterns [35]. At loci under selection, local adaptation and directional selection should reduce genetic variability within populations and increase variation among populations. Loci used in population genomics studies include microsatellites, single nucleotide polymorphisms (SNPs), amplified fragment length polymorphisms (AFLPs), randomly amplified polymorphic DNA (RAPDs), and sequences (e.g., whole-genome sequences). Many genetic markers can be generated without a sequenced genome relatively easily and genomes can be mined without measuring phenotypes, allowing for sampling of individuals without knowing their breeding history. For example, SNP analysis can be performed by mining EST data collections for putative SNPs [36]. If the ESTs were derived from multiple individuals (and multiple populations of interest), putative SNPs can be identified in sequence alignments. Conveniently, any SNPs identified as important through population genomic approaches are already associated with a sequenced gene transcript.

Custom SNP genotyping platforms provide efficient genotyping of thousands of individuals, resulting in biologically important sequence variations from multiple populations. The advantage of AFLPs and RAPDs is that, again, no prior sequence information is necessary. The drawback is that AFLP and RAPD analyses depend on high-quality DNA and provide only dominant markers, so heterozygotes cannot be directly measured, and generated markers are often anonymous or in a nonfunctional area of the genome. Genome-wide association studies (GWAS) are challenging with non-model organisms because they lack an abundance of readily available, high quality, sequenced genomes, and genome-wide genotyping data. To improve the use of NGS data obtained from non-model organisms, new imputation methods such as Link Imputer [37] help infer missing genotypes and facilitate the analysis of non-model organisms sequencing data.

Susceptibility to toxic substances depends on the organism’s genotype and interactions with the polluted environment. Natural populations inhabit spatially and temporally uncontrolled environments where pollutants are present as complex mixtures, so the challenges of “omics” technologies with natural populations are the challenges of basic biological research: which data is biologically meaningful? Considering cost, challenging sample material, lack of biological replicates, and complexity of genotype-environment interactions, choosing an optimal method is difficult. Yet, instead of a single gene, protein, or polymorphism, one can analyze thousands of genes, proteins, and polymorphisms utilizing biologically realistic, genetically variable individuals, extrapolating a population response rather than a strain-specific one. Complementary “omics” approaches offer a better understanding of biological effects at multiple levels: model-organisms are used to study many important questions in biology, population genomics provide insights into the sequence variations that govern differences in gene expression and protein polymorphisms, while transcriptomics provides insights into altered protein levels. A focused approach, using known POP inducers and inhibitors present in such mixtures and analyzing responses of cellular and tissue targets, can provide insights into mechanisms of toxicity seen in natural populations and help devise a more comprehensive risk assessment strategy. Thus, just as the integration of laboratory and field studies improves our knowledge of genes and proteins, so is the integration of laboratory and field studies critical for “omic” approaches and public health risk assessment modeling.

Read More About this Article: https://biomedgrid.com/fulltext/volume5/hybrid-rice-technology-an-overview.000865.php

For more about: Journals on Biomedical Science :Biomed Grid | Current Issue

[sachincmi]

SNP Genotyping and Analysis Market to Gain Excellent Traction as Industry Leaders Continue R&D Activities to discover SARS-CoV-2 variants

Single nucleotide polymorphism (SNP) genotyping refers to the measurement of DNA differences between individuals belonging to a particular species. It's a form of genomics, which basically is the analysis of general genetic variation in the human body. SNP genotyping and analysis involves obtaining DNA samples from the blood or tissue samples of various people. The DNA is extracted by using centrifugal pressure and then examined with a DNA sequencing machine. The results are analyzed, then compared with previous samples collected. There are different methods that are employed in measuring genetic differences between people, although there are some that seem to be the most popular.

There are a variety of reasons why the SNP is needed for a DNA test. SNPs can be used to prove the existence of certain diseases, such as breast cancer, diabetes, or asthma. They can also provide insight into the cause of diseases, like Alzheimer's disease, to find out if the disease may have a genetic basis. CSNB stands for the Coding Single Nucleotide Frame Analysis and it is one of the oldest and most effective methods. It was first used by the Swedish government back in 1970, to assess the potential health risks of women using estrogen.

Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/snp-genotyping-and-analysis-market-to.html

[the-madhuri]

Global Biochip Scanner Market-Industry Analysis and Forecast (2019-2027) – By Type, End User, and Region.

Global biochip scanner market size was US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of ~18% during the forecast period.

Global Biochip Scanner Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Biochips are miniature version of the laboratories and are the most significant part of molecular biology. Biochips are generally used to perform thousands or hundreds of biochemical reactions at the same time. A biochip scanner is a device that is used to discover and obtain fluorescence signal data from biochips or biological microchips and these devices consist of a laser to emit a laser beam and scan the particular rows of the biochips.

Market Dynamics

A biochip scanner market has witnessed an ample growth from the past few years. The growth of the biochip scanner market is primarily driven by its growing significance in various biomedical applications. An increasing requirement to reduce turnaround time, rising demand of biochip scanners for researches and diagnostics activities to perform clinical tests, growing technological advancements and rising applications of biochips, ongoing research and development activities in large-scale genomic and proteomic field and advances in nanotechnology are expected to improve growth of the market during the forecast period.

However, high cost of biochip scanners, risks of hazardous problems of individual privacy and high complexity of biological systems are major restraining factors that could hamper the growth of the market.

Global Biochip Scanner Market: Segmentation Analysis

By type, the DNA chip segment dominated the market in 2019 and is projected to witness fast growth at a CAGR of XX% during the forecast period. Increasing investments in research activities and rising demand for next-generation and advanced genetic disorder diagnosis and detection tools are attributed to the growth of the market. A rising adoption of DNA chips in applications such as gene expression profiling, to identify novel drugs, to discover the dissimilarities in gene expression levels in cells and to detect the mutations in specific genes is expected to improve growth of the market during the forecast period.

Global Biochip Scanner Market: Regional Analysis

Region-wise, North America held the largest market share in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major key contributors behind the growth of the market. The growth is attributed to the growing technological advancements in the biomedical field across the region.

Growing adoption of biochip scanners in research laboratories and increasing use of biochip scanning technology in drug development, clinical research, toxicology studies, diagnostics and in various clinical trials is driving the growth of the market in the NA region.

The objective of the report is to present a comprehensive analysis of the Global Biochip Scanner Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Biochip Scanner Market dynamics, structure by analyzing the market segments and projects the Global Biochip Scanner Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biochip Scanner Market make the report investor’s guide.

For more information visit the link given belowhttps://www.maximizemarketresearch.com/market-report/global-biochip-scanner-market/70484/

The Scope of Global Biochip Scanner Market

Global Biochip Scanner Market, By Type

• DNA Chips • Lab-On-A-Chip • Protein Chips • Cancer Diagnosis and Treatment • Gene Expression • Single Nucleotide Polymorphism (SNP) Genotyping • Genomics • Drug Discovery • Others (Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening) Global Biochip Scanner Market, By End User

• Biotechnology & Pharmaceutical Companies • Hospitals & Diagnostics Centers • Academic & Research Institutes Global Biochip Scanner Market, By Region

• North America  US  Canada • Europe  UK  France  Germany  Italy  Spain  Norway  Russia • Asia Pacific  China  India  Japan  South Korea  Australia  Malaysia  Indonesia • South America  Brazil  Mexico  Argentina • Middle East and Africa Global Biochip Scanner Market, Key Players

• Agilent Technologies, Inc • Bio-Rad Laboratories, Inc • Cepheid Inc • Fluidigm Corporation • GE Healthcare • Hoffman-La-Roche Ltd • Illumina, Inc • Ocimum Biosolutions Ltd • PerkinElmer, Inc • Takara Bio Inc • Thermo Fisher Scientific Inc • Merck Millipore • Sigma-Aldrich Corporation • Abbott Laboratories • XX • XX

This report is submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908